Literature DB >> 5139989

The fibrinolytic enzyme system in hepatic cirrhosis and malignant metastases.

D Ogston, N B Bennett, C M Ogston.   

Abstract

Components of the blood fibrinolytic system were measured in 18 patients with hepatic cirrhosis, in two patients with acute hepatic necrosis, and in 10 patients with hepatic metastases. The frequency of an elevation of plasminogen activator and a reduction in plasminogen in hepatic cirrhosis has been confirmed. Patients with compensated cirrhosis had low levels of the serum inhibitor of plasminogen activation while those with severe hepatic insufficiency or coma due to cirrhosis or hepatic necrosis had elevated levels. The presence of hepatic metastases was associated with reduced plasminogen activator levels and an increase in the fibrinogen concentration.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5139989      PMCID: PMC477192          DOI: 10.1136/jcp.24.9.822

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  26 in total

1.  ROLE OF INHIBITORS OF FIBRINOLYSIS IN HEPATIC CIRRHOSIS.

Authors:  R A O'CONNELL; C E GROSSI; L M ROUSSELOT
Journal:  Lancet       Date:  1964-11-07       Impact factor: 79.321

2.  Cellular localization of profibrinolysin (plasminogen).

Authors:  M I BARNHART; J M RIDDLE
Journal:  Blood       Date:  1963-03       Impact factor: 22.113

3.  Coagulation defects in patients with cirrhosis of the liver undergoing portasystemic shunts.

Authors:  C E GROSSI; L M ROUSSELOT; W F PANKE
Journal:  Am J Surg       Date:  1962-10       Impact factor: 2.565

4.  Studies on enhanced fibrinolytic activity in man.

Authors:  S SHERRY; R I LINDEMEYER; A P FLETCHER; N ALKJAERSIG
Journal:  J Clin Invest       Date:  1959-05       Impact factor: 14.808

5.  xi-Aminocaproic acid: an inhibitor of plasminogen activation.

Authors:  N ALKJAERSIG; A P FLETCHER; S SHERRY
Journal:  J Biol Chem       Date:  1959-04       Impact factor: 5.157

6.  Antifibrinolytic activity in primary carcinoma of the liver.

Authors:  H C KWAAN; R LO; A J MCFADZEAN
Journal:  Clin Sci       Date:  1959-05       Impact factor: 6.124

7.  Plasma fibrinolytic activity in cirrhosis of the liver.

Authors:  H C KWAAN; A J MCFADZEAN; J COOK
Journal:  Lancet       Date:  1956-01-21       Impact factor: 79.321

8.  Fibrinolysis at rest and after exercise in hepatic cirrhosis.

Authors:  P C Das; J D Cash
Journal:  Br J Haematol       Date:  1969-11       Impact factor: 6.998

9.  The defibrination syndrome: clinical features and laboratory diagnosis.

Authors:  C Merskey; A J Johnson; G J Kleiner; H Wohl
Journal:  Br J Haematol       Date:  1967-07       Impact factor: 6.998

10.  Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease.

Authors:  C M Ogston; D Ogston
Journal:  J Clin Pathol       Date:  1966-07       Impact factor: 3.411

View more
  3 in total

1.  Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.

Authors:  N A Booth; J A Anderson; B Bennett
Journal:  J Clin Pathol       Date:  1984-07       Impact factor: 3.411

2.  Fibrinolytic activity in malignant disease.

Authors:  J A Rennie; D Ogston
Journal:  J Clin Pathol       Date:  1975-11       Impact factor: 3.411

3.  Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis?

Authors:  Valeria Rossetto; Luca Spiezia; Marco Senzolo; Krissia Isabel Rodriguez-Castro; Sabrina Gavasso; Barry Woodhams; Paolo Simioni
Journal:  Intern Emerg Med       Date:  2013-03-17       Impact factor: 3.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.